Qeen Biotechnologies Inc., a leader in bacteriophage-based solutions, is proud to announce its role in providing bacteriophage therapy for a Canadian patient suffering from a periprosthetic joint infection (PJI) caused by an antimicrobial-resistant (AMR) pathogen. This groundbreaking treatment marks a significant milestone in the fight against AMR infections, offering not only clinical benefits but also significant economic advantages.
The patient, treated by Dr. Stephen Vaughan, received targeted phage therapy developed to combat drug-resistant pathogens. Unlike traditional treatments that often rely on prolonged antibiotic regimens and costly two-stage revision surgeries—which can cost up to $50,000 per procedure in Canada—bacteriophage therapy provides a more cost-effective alternative. By precisely targeting the infection and reducing the need for extensive hospital stays, additional surgeries, and high-cost antibiotics, phage therapy has the potential to significantly lower healthcare costs while improving patient outcomes. In many cases, Canadian clinicians are forced to procure costly antibiotics, not approved domestically, from the United States, further adding to the financial strain on the healthcare system. The human cost is equally devastating, as many patients with multidrug-resistant PJIs face life-altering amputations or, tragically, death when conventional therapies fail. Qeen Biotechnologies is hopeful that the Canadian government will take steps to mobilize reimbursement policies for the costs associated with the manufacture and delivery of these life-saving phages.
Entdecke mehr von LabNews
Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.
